Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: A randomized, double-blind, placebo-controlled trial

Pain

Volumn 157, Issue 9, 2016, Pages 2097-2103

  Andresen, Sven R ^a   Bing, Jette ^b   Hansen, Rikke M ^a   Biering Sørensen, Fin ^b   Johannesen, Inger L ^a   Hagen, Ellen Merete ^a,c,d   Rice, Andrew S C ^e   Nielsen, Jørgen F ^f   Bach, Flemming W ^g   Finnerup, Nanna B ^h  

^a VIBORG HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF BERGEN   (Norway)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f Hammel Neurorehabilitation and Research Centre   (Denmark)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h AARHUS UNIVERSITY   (Denmark)

Author keywords

Neuropathic pain; PEA; Randomized controlled trial; Spasticity; Spinal cord injury; Ultramicronized palmitoylethanolamide

Indexed keywords

PALMIDROL; PLACEBO; ULTRAMICRONIZED PALMITOYLETHANOLAMIDE; UNCLASSIFIED DRUG; ANALGESIC AGENT; ETHANOLAMINE DERIVATIVE; PALMITIC ACID DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; CHOLELITHIASIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ERYSIPELAS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; MYCOSIS; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN INTENSITY; PARALYTIC ILEUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPASTICITY; SPINAL CORD INJURY; URINARY TRACT INFECTION; AGED; ANALYSIS OF VARIANCE; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; NEURALGIA; TREATMENT OUTCOME;

ADULT; AGED; ANALGESICS; ANALYSIS OF VARIANCE; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEURALGIA; PALMITIC ACIDS; SPINAL CORD INJURIES; TREATMENT OUTCOME;

EID: 84984621812     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000623     Document Type: Article

References (42)

1. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T,DiMarzo V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001;15:300-2
2. Bech P, Rasmussen NA, Olsen LR, Noerholm V, Abildgaard W. The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. J Affect Disord 2001;66:159-64
3. Bech P, Wermuth L. Applicability and validity of the major depression inventory in patients with Parkinson's disease. Nord J Psychiatry 2015; 52:305-9
4. Biering-Sorensen F, Nielsen JB, Klinge K, Biering-Sørensen F. Spasticityassessment: a review. Spinal Cord 2006;44:708-22
5. Bryce TN, Biering-Sørensen F, Finnerup NB, Cardenas DD, Defrin R, Lundeberg T, Norrbrink C, Richards JS, Siddall P, Stripling T, Treede R-D, Waxman SG, Widerström-Noga E, Yezierski RP, Dijkers M. International spinal cord injury pain classification: part I. background and description. Spinal Cord 2012;50:413-7
6. Canteri L, Petrosino SGG. Reducción del consumo de antiinflamatorios y analgésicos en el tratamiento del dolor neuropático crónico en pacientes afectados por lumbociatalgia de tipo compresivo y en tratamiento con Normast 300 mg. Dolol 2010;25:227-34
7. Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat 2014;2014:854560
8. Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, Jensen MP, Katz NP, Raja SN, Rappaport BA, Rowbotham MC, Backonja M-M, Baron R, Bellamy N, Bhagwagar Z, Costello A, Cowan P, Fang WC, Hertz S, Jay GW, Junor R, Kerns RD, Kerwin R, Kopecky EA, Lissin D, Malamut R, Markman JD, McDermott MP, Munera C, Porter L, Rauschkolb C, Rice ASC, Sampaio C, Skljarevski V, Sommerville K, Stacey BR, Steigerwald I, Tobias J, Trentacosti AM, Wasan AD, Wells GA, Williams J, Witter J, Ziegler D. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 2012;153:1148-58
9. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162-73
10. Finnerup NB, Norrbrink C, Trok K, Piehl F, Johannesen IL, Sørensen JC, Jensen TS, Werhagen L. Phenotypes and predictors of pain following traumatic spinal cord injury: a prospective study. J Pain 2014;15:40-8
11. Guida G, de Fabiani A, Lanaia F, Alexandre A, Vassallo GM, Cantieri L, de Martino M, Rogai M, Petrosino S. La palmitoiletanolamida (Normast) en el dolor neuropático crónico por lumbociatalgia de tipo compresivo: estudio clínico multicéntrico. Dolol 2010;25:35-42
12. Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med 2012;13:1121-30
13. Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomelli D, Calignano A, Cuzzocrea S. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther 2008;326:12-23
14. Haroutiunian S, Donaldson G, Yu J, Lipman AG. Development and validation of shortened, restructured treatment outcomes in pain survey instrument (the S-TOPS) for assessment of individual pain patients' health-related quality of life. Pain 2012;153:1593-601
15. Helyes Z, Németh J, Thán M, Bölcskei K, Pintér E, Szolcsányi J. Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci 2003;73: 2345-53
16. Hesselink J. New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide. Open Pain J 2012;5:12-23
17. Hesselink JMK. Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-A agonist and effective nutraceutical. J Pain Res 2013;6:625-34
18. Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, Esposito E, Cuzzocrea S. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation 2014;11:136
19. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998;76:189-99
20. Kirshblum SC, Burns SP, Biering-Sorensen F, Donovan W, Graves DE, Jha A, Johansen M, Jones L, Krassioukov A, Mulcahey MJ, Schmidt-Read M, Waring W. International standards for neurological classification of spinal cord injury (revised 2011). J Spinal Cord Med 2011;34:535-46
21. Lambert DM, Vandevoorde S, Jonsson K-O, Fowler CJ. The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 2002;9:663-74
22. Lever IJ, Rice ASC. Cannabinoids and pain. Handb Exp Pharmacol 2007; 177:265-306
23. Maione S, Costa B, Di Marzo V. Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain 2013;154 suppl 1:S87-93
24. Marino RJ, Barros T, Biering-Sorensen F, Burns SP, Donovan WH, Graves DE, Haak M, Hudson LM, Priebe MM. International standards for neurological classification of spinal cord injury. J Spinal Cord Med 2003; 26 suppl 1:S50-6
25. Mattace Raso G, Russo R, Calignano A, Meli R. Palmitoylethanolamide in CNS health and disease. Pharmacol Res 2014;86:32-41
26. Morin CM, Belleville G, Bélanger L, Ivers H. The insomnia severity index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep 2011;34:601-8
27. Olsen LR, Jensen DV, Noerholm V, Martiny K, Bech P. The internal and external validity of themajor depression inventory in measuring severity of depressive states. Psychol Med 2003;33:351-6
28. Pandyan AD, Gregoric M, Barnes MP, Wood D, Van Wijck F, Burridge J, Hermens H, Johnson GR. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 2005;27:2-6
29. Paterniti I, Impellizzeri D, Di Paola R, Navarra M, Cuzzocrea S, Esposito E. A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury. J Neuroinflammation 2013;10:91
30. Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S, Di Marzo V. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 2007;52:415-22
31. Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 2007;173:21-30
32. Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat 2014;2014:849623
33. Sheean G. The pathophysiology of spasticity. Eur J Neurol 2002;9 suppl 1:3-9; discussion 53-61
34. Siddall PJ, McClelland JM, Rutkowski SB, Cousins MJ. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 2003;103:249-57
35. Skaper SD, Facci L, BarbieratoM, Zusso M, Bruschetta G, Impellizzeri D, Cuzzocrea S, Giusti P. N-Palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution. Mol Neurobiol 2015;52: 1034-42
36. Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, Giusti P. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology 2014;22:79-94
37. Tardieu G, Shentoub G, Shentoub S, Delarue R. Research on a technic for measurement of spasticity. Rev Neurol (Paris) 1954;91:143-4
38. Treede R-D, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5
39. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005;67:15-9
40. Wallace VCJ, Segerdahl AR, Lambert DM, Vandevoorde S, Blackbeard J, Pheby T, Hasnie F, Rice ASC. The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. Br J Pharmacol 2007;151:1117-28
41. Widerström-Noga E, Biering-Sørensen F, Bryce T, Cardenas DD, Finnerup NB, Jensen MP, Richards JS, Siddall PJ. The international spinal cord injury pain basic data set. Spinal Cord 2008;46:818-23
42. Woodhams SG, Sagar DR, Burston JJ, Chapman V. The role of the endocannabinoid system in pain. Handb Exp Pharmacol 2015;227: 119-43